- Transcenta Therapeutics and its subsidiary HJB have signed a technology licensing and strategic collaboration agreement with WuXi Biologics covering selected technologies from Transcenta’s HiCB platform and ExcelPro cell culture media.
- Transcenta will receive an upfront payment of RMB 10 million ($1.49 million), with potential additional milestone payments, while WuXi Biologics will support CMC development across Transcenta’s pipeline.
Transcenta Therapeutics and its subsidiary HJB have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics. Under the agreement, WuXi Biologics and its affiliates will receive a non-exclusive license to selected technologies from Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform and ExcelPro cell culture media. The companies did not disclose the specific licensed technologies.
Transcenta will receive an upfront payment of RMB 10 million ($1.49 million) and could receive additional milestone payments if agreed conditions are met. As part of the strategic collaboration, WuXi Biologics will also support CMC development and work with molecules across Transcenta’s pipeline.
The HiCB platform combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification. According to Transcenta, the platform is designed to increase productivity compared with conventional fed-batch processes while maintaining quality through shorter residence times and optimized culture conditions. The company said the approach is also designed to lower cost of goods and capital investment, enable just-in-time production, and improve recovery yield and product quality for complex biologics.
The agreement supports Transcenta’s strategy of expanding partnerships around its HiCB platform and addressing CMC challenges associated with complex biologics. The company said the collaboration is intended to provide a more flexible path to scaling production capacity.
Transcenta said it will continue pursuing external licensing and industry partnerships as it seeks to expand the commercial value of the HiCB platform.
